Cipla Health "Naselin Shubhratri, Prajapati - The Guard" campaign wins Silver at Effie APAC Awards 2022
Naselin has been recognized out of the 29 Indian brands and from the total of 107 brands across the Asia Pacific region which is a gratifying moment for the brand.
Mumbai: Naselin, the nasal decongestant brand by Cipla Health has won the "Silver" at the Effie APAC Awards for its captivating yet appealing "Naselin Shubhratri, Prajapati - The Guard" campaign.
Naselin becomes Cipla's first ever brand to win a marketing award in the Asian Pacific region, which is one of the industry's most distinguished accolades for marketing effectiveness. APAC Effie Awards are globally recognized as the gold standard for agencies and clients alike.
The Asia Pacific Effie Awards honours the region's most outstanding marketing communication works that have proven results in meeting strategic objectives. The Effie Awards are known by advertisers and agencies globally as the pre‐eminent award in the industry. Introduced by the New York American Marketing Association in 1968, the Effie Awards have since been recognized by advertisers and agencies as the global gold standard of marketing effectiveness excellence. The award now recognises and celebrates the most effective brands, marketers and agencies, globally, regionally and locally through its 50 plus award programmes across the world and through its coveted effectiveness rankings - the Effie Index.
Naselin has been recognized out of the 29 Indian brands and from the total of 107 brands across the Asia Pacific region which is a gratifying moment for the brand.
Naselin's Nasal Decongestant spray contains Oxymetazoline Hydrochloride which aids in fast relief from clogged nose and sinus congestion and so offers relief over a larger area.
Speaking on the win, Shivam Puri, CEO – Cipla Health says, "I am truly pleased and humbled by this recognition being bestowed on Cipla Health. These awards are a reflection of our purposeful strides and our relentless commitment to address the unmet needs of our consumers. Driven by deep consumer insights and marketing expertise, Cipla Health has always strived to enhance the lives of our consumers with the most innovative and effective solutions."
Cipla Health Ltd. (CHL), the consumer healthcare subsidiary of Cipla Ltd. was founded in the year 2016. CHL offers a folio of diverse brands, including Nicotex, Cofsils, Prolyte, Mamaxpert, Maxirich, Clocip, Naselin, Ciphands, and Cipladine among others.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.